(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 12.80%
-0.91% $ 16.36
@ $10.44
Wydano: 13 vas. 2024 @ 17:07
Zwrot: 56.66%
Poprzedni sygnał: vas. 12 - 20:04
Poprzedni sygnał:
Zwrot: -6.09 %
Live Chart Being Loaded With Signals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 10 535.00 |
Średni wolumen | 29 570.00 |
Kapitalizacja rynkowa | 96.43M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-1.940 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.830 |
ATR14 | $0.145 (0.88%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-01 | Zung Jonathan B. | Buy | 500 000 | Employee stock option (right to buy) |
2023-05-01 | Zung Jonathan B. | Buy | 0 | |
2023-01-23 | Kaitin Kenneth I | Buy | 85 000 | Non Qualified Stock Option |
2023-01-23 | Hohneker John | Buy | 85 000 | Non Qualified Stock Option |
2023-01-23 | Rubin Marc | Buy | 85 000 | Non Qualified Stock Option |
INSIDER POWER |
---|
86.47 |
Last 97 transactions |
Buy: 14 857 117 | Sell: 1 304 959 |
Curis Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
BUR | 0.887 |
ARCT | 0.884 |
PSTV | 0.882 |
IFRX | 0.882 |
FTRI | 0.881 |
EZFL | 0.878 |
CWBC | 0.876 |
VTSI | 0.866 |
SBET | 0.864 |
MDRR | 0.861 |
10 Najbardziej negatywne korelacje | |
---|---|
AMRB | -0.912 |
PKOH | -0.886 |
SMH | -0.881 |
SNCY | -0.873 |
AMRS | -0.856 |
CHB | -0.852 |
GPRE | -0.85 |
VOXX | -0.846 |
FLDM | -0.844 |
VTRU | -0.833 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Curis Inc Finanse
Annual | 2023 |
Przychody: | $10.02M |
Zysk brutto: | $9.81M (97.88 %) |
EPS: | $-8.96 |
FY | 2023 |
Przychody: | $10.02M |
Zysk brutto: | $9.81M (97.88 %) |
EPS: | $-8.96 |
FY | 2022 |
Przychody: | $10.16M |
Zysk brutto: | $9.91M (97.47 %) |
EPS: | $-12.92 |
FY | 2021 |
Przychody: | $10.65M |
Zysk brutto: | $10.12M (94.99 %) |
EPS: | $-0.500 |
Financial Reports:
No articles found.
Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej